About the Beijing AI Center

The Beijing AI Center is a new strategic investment by AstraZeneca to accelerate drug discovery through AI. The center brings together AI researchers, computational scientists, and platform engineers to apply foundation models, agentic AI, and large-scale scientific computing to real R&D problems. Situated in one of the world's most dynamic AI talent markets, the center operates at the intersection of AI and biologics discovery, computational chemistry, and data-driven drug development.

The center is structured around three pillars: Discovery verticals (biologics engineering, computational chemistry) that own the science, Data & AI Platforms (this role) that own the capabilities, and R&D IT that owns the infrastructure. A dedicated on-premises GPU cluster provides the compute backbone, operated by IT and shaped by platform standards.

About the Role

This role owns the AI capability layer for the Beijing AI Center: the ...